By Healthcare Edge Editorial Staff
Octave Bioscience, Inc. said Founder William Hagstrom will become Chairman of the Board, while Doug Biehn is the new President and CEO.
Mr. Biehn has over 20 years of experience in healthcare, building and scaling growth businesses, the company, which treats neurodegenerative diseases, wrote in a statement.
Before joining Octave, Mr. Biehn held executive leadership roles at iRhythm Technologies, McKesson, AliveCor, Blue Shield of California and Cala Health, it said.
“It’s a privilege to build upon the foundation of innovative science and technology that Bill and the team have created and lead the company through its next phase of growth,” said Mr. Biehn.